SS Innovations International (NASDAQ: SSII) has reported significant growth in the utilization of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of Sept. 8, 2026—a 79% increase from 7,885 at the end of 2025. The installed base of SSi Mantra systems grew 42% to 238 units, up from 168, according to the company’s recent update. This expansion underscores the accelerating adoption of robotic-assisted surgery, particularly in emerging markets where access to advanced medical technology has traditionally been limited.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the platform. The system has been used for more than 170 types of surgical procedures, demonstrating its versatility. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the company’s success in penetrating diverse healthcare markets and addressing a broad range of surgical needs.
In addition to its general surgery applications, SS Innovations has emphasized its growing footprint in pediatric and telesurgery. As of Aug. 31, the company reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries, including a more than 13,600-mile telesurgery between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, showcasing the system’s efficiency and reliability in high-volume settings.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. The company also believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones, if achieved, would open doors to two of the world’s largest healthcare markets, potentially driving further adoption and revenue growth. For investors, the timeline provides clarity on upcoming catalysts that could significantly impact the company’s valuation.
The broader implications of this announcement extend beyond SS Innovations. The company’s focus on making robotic surgery affordable and accessible could disrupt the surgical robotics market, which has historically been dominated by high-cost systems. By offering a cost-effective alternative, SS Innovations may enable hospitals in developing countries to adopt robotic surgery, improving patient outcomes and expanding the overall market. The company’s progress in telesurgery also points to a future where remote surgical expertise can be delivered across vast distances, potentially transforming healthcare delivery in underserved regions.
For more details, the full report is available at https://ibn.fm/DJILj. The latest news and updates relating to SSII can be found at https://ibn.fm/SSII. As with any forward-looking statements, actual results may differ materially due to various risks and uncertainties.
